Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (17026)	7/8/2004 12:08:22 AM
From: Robert K.	Read Replies (7) \| Respond to of 17367

Blue> its NOT that I dont think raptiva will find usefullness across many things , it just that its a race against time. And time will bring BETTER anti-lfa-1's than raptiva. I aint too worried about the statins but I do have a close watch on what dna is doing to better Raptiva. Still>a approved product is worth a bundle vs a preclinical improvement. In the interm this "statin" list is a good hint as to what the partners might have in ming. ."Regarding the above facts and in view of their safety and inexpensiveness, statins may prove invaluable in the treatment of a multiplicity of dermatologic disorders, especially those characterized by ingress of activated leucocytes into the skin, such as alopecia areata, vitiligo, lichen planus, subacute cutaneous lupus erythematosus, erythema multiforme, psoriasis, bullous pemphigoid, systemic sclerosis, mycosis fungoides, toxic epidermal necrolysis and Behcet's disease."